AACR Recap: Updates in Liquid Biopsy

Wednesday, June 2 2021 at 1:00 p.m. ET

A recap of AACR with highlights of liquid biopsy MRD, methylation, and whole genome CNV

The liquid biopsy landscape is changing rapidly. Predicine is advancing the clinical utility of liquid biopsy more broadly across the continuum of cancer care. We are innovating our liquid biopsy technology to detect a range of genomic signatures that will impact clinical care in the future. 

During this webinar we will highlight Predicine’s liquid biopsy advancement in minimal residual disease (MRD), methylation, and low-pass whole genome detection of copy number variations (CNV), presented at AACR 2021. Come join us to learn more about where liquid is going!

Date: Wednesday, June 2, 2021
Time: 1:00 PM EDT / 10 AM PDT

Topics to be covered:

  • Flexible approaches to MRD, unbounded by tissue availability 
  • Low-pass whole genome detection of CNV
  • Enhanced detection of methylations

Register Now


Title: AACR Recap: Updates in Liquid Biopsy

Date: Wednesday, June 2, 2021

Time: 1:00pm Eastern Standard Time

Duration: 40 minutes